Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
229 hedge funds and large institutions have $2.63B invested in Clovis Oncology, Inc. in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 84 increasing their positions, 80 reducing their positions, and 40 closing their positions.
69% more call options, than puts
Call options by funds: $86.1M | Put options by funds: $50.8M
5% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 80
7% less funds holding
Funds holding: 247 → 229 (-18)
25% less capital invested
Capital invested by funds: $3.5B → $2.63B (-$863M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$56.3M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$38M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$32.3M |
| 4 |
AC
Armistice Capital
New York
|
+$27.3M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$89.8M |
| 2 |
HM
HealthCor Management
New York
|
-$66.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$49.9M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$32.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$31.7M |
CLVS Hedge Fund Activity: Q1 2018 in Review
229 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2018, worth a combined $2.63B — down 25% from $3.5B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of CLVS and 28 opened new positions — a net loss of 12 holders — while 80 trimmed existing stakes and 84 added.
The largest buyer was Citadel Advisors, adding an estimated $56.3M. The largest seller was Redmile Group, exiting entirely with an estimated $89.8M sold.
- 229 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2018, down from 247 in Q4 2017.
- Funds reported $2.63B of Clovis Oncology, Inc. stock for Q1 2018, down 25% quarter-over-quarter.
- 28 funds opened new Clovis Oncology, Inc. positions in Q1 2018 and 40 closed out, a net change of -12 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $56.3M added.
- The largest Clovis Oncology, Inc. seller in Q1 2018 was Redmile Group, an estimated $89.8M sold.
Based on aggregated 13F filings for Q1 2018.